Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Mansinho A, Macedo D, Fernandes I, et al. Castration-resistant prostate Cancer: mechanisms, targets and treatment. Adv Exp Med Biol. 2018;1096:117–33.

Article  PubMed  Google Scholar 

Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol. 2021;79:263–82.

Article  PubMed  Google Scholar 

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

Article  PubMed  Google Scholar 

de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

Article  PubMed  PubMed Central  Google Scholar 

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.

Article  PubMed  Google Scholar 

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

Article  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with Chemotherapy-naïve metastatic castration-resistant prostate Cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4.

Article  PubMed  Google Scholar 

Mateo J, Boysen G, Barbieri CE, et al. DNA repair in prostate Cancer: Biology and Clinical implications. Eur Urol. 2017;71:417–25.

Article  PubMed  Google Scholar 

Rose M, Burgess JT, O’Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020;8:564601.

Article  PubMed  PubMed Central  Google Scholar 

Tisseverasinghe S, Bahoric B, Anidjar M, et al. Advances in PARP inhibitors for prostate Cancer. Cancers (Basel). 2023;15:1849.

Article  PubMed  Google Scholar 

Chi KN, Rathkopf D, Smith MR, et al. Niraparib and Abiraterone acetate for metastatic castration-resistant prostate Cancer. J Clin Oncol. 2023;41:3339–51.

Article  PubMed  PubMed Central  Google Scholar 

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:EVIDoa2200043.

Article  PubMed  Google Scholar 

Agarwal N, Azad AA, Carles J, et al. Talazoparib plus Enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291–303.

Article  PubMed  Google Scholar 

Tanaka A, Node K. The Emerging and Promising Role of Care for Cardiometabolic syndrome in prostate Cancer. JACC CardioOncol. 2019;1:307–9.

Article  PubMed  PubMed Central  Google Scholar 

Yadav MP, Ballal S, Sahoo RK, et al. Radioligand Therapy with 177Lu-PSMA for metastatic castration-resistant prostate Cancer: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2019;213:275–85.

Article  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

Article  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091–103.

Article  PubMed  PubMed Central  Google Scholar 

Satapathy S, Mittal BR, Sood A, et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022;49:1754–64.

Article  PubMed  Google Scholar 

Satapathy S, Mittal BR, Sood A, et al. [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve metastatic castration-resistant prostate Cancer: final survival analysis of a phase 2 Randomized, Controlled Trial. J Nucl Med. 2023;64:1726–9.

Article  PubMed  Google Scholar 

Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. 177 Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis. Prostate. 2022;82:826–35.

Article  PubMed  PubMed Central  Google Scholar 

Scher HI, Morris MJ, Stadler WM, et al. Trial Design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials Working Group 3. J Clin Oncol. 2016;34:1402–18.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

Article  PubMed  Google Scholar 

Sartor O, Castellano Gauna DE, Herrmann K, et al. LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol. 2023;34(Suppl 2):S1324–5.

Article  Google Scholar 

Satapathy S, Das N, Sood A, et al. Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume metastatic hormone-sensitive prostate Cancer: time to take the Leap? Eur Urol. 2021;80:390–2.

Article  PubMed  Google Scholar 

Privé BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate Cancer: a prospective pilot study. Clin Cancer Res. 2021;27:3595–601.

Article  PubMed  Google Scholar 

Shore ND, Laliberté F, Ionescu-Ittu R, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate Cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38:4520–40.

Article  PubMed  PubMed Central  Google Scholar 

Galli L, Chiuri VE, Di Lorenzo G, et al. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the prostate Cancer Registry. Tumori. 2023;109:224–32.

Article  PubMed  Google Scholar 

Shayegan B, Wallis CJD, Malone S, et al. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. Urol Oncol. 2022;40:e1921–9.

Article  Google Scholar 

Anton A, Pillai S, Semira MC, et al. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI Compass. 2021;3:205–13.

Article  PubMed  PubMed Central  Google Scholar 

Chowdhury S, Bjartell A, Lumen N, et al. Real-world outcomes in First-Line treatment of metastatic castration-resistant prostate Cancer: the prostate Cancer Registry. Target Oncol. 2020;15:301–15.

Article  PubMed  PubMed Central  Google Scholar 

Bjartell A, Lumen N, Maroto P, et al. Real-world safety and efficacy outcomes with abiraterone acetate plus prednisone or prednisolone as the First- or second-line treatment for metastatic castration-resistant prostate Cancer: data from the prostate Cancer Registry. Target Oncol. 2021;16:357–67.

Article  PubMed  PubMed Central  Google Scholar 

Freedland SJ, Davis M, Epstein AJ et al. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2023 Oct 2. https://doi.org/10.1038/s41391-023-00725-8. Epub ahead of print.

George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate Cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284–94.

Article  PubMed  Google Scholar 

Satapathy S, Sahoo RK, Bal C. [177Lu]Lu-PSMA-Radioligand Therapy Efficacy outcomes in Taxane-Naïve Versus taxane-treated patients with metastatic castration-resistant prostate Cancer: a systematic review and metaanalysis. J Nucl Med. 2023;64:1266–71.

Article  PubMed  Google Scholar 

Privé BM, Slootbeek PHJ, Laarhuis BI, et al. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:71–8.

Article  PubMed  Google Scholar 

Satapathy S, Das CK, Aggarwal P, et al. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: a single-center experience. Prostate. 2023;83:169–78.

Article  PubMed  Google Scholar 

Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate Cancer treated with 177Lu-Labeled prostate-specific membrane Antigen Radioligand Therapy: a systematic review and Meta-analysis. Clin Nucl Med. 2020;45:935–42.

Article  PubMed  Google Scholar 

Mehrens D, Kramer KKM, Unterrainer LM, et al. Cost-effectiveness analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-resistant prostate Cancer. J Natl Compr Canc Netw. 2023;21:43–e502.

Article  PubMed  Google Scholar 

Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014;12:1417–25.

Article  PubMed  Google Scholar